These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 11125232)
1. Bacteroides fragilis-induced intra-abdominal abscess in an experimental model treated with telithromycin (HMR 3647). Thadepalli H; Chuah SK; Qazi S; Thadepalli F; Gollapudi SV Chemotherapy; 2001; 47(1):43-9. PubMed ID: 11125232 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of telithromycin in the treatment of experimental Bacteroides fragilis intraabdominal abscess in the senescent mice. Thadepalli H; Chuah SK; Vidad A; Gollapudi S Infez Med; 2004 Mar; 12(1):44-50. PubMed ID: 15329528 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Thadepalli H; Chuah SK; Gollapudi S Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081 [TBL] [Abstract][Full Text] [Related]
4. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. Credito KL; Ednie LM; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1999 Aug; 43(8):2027-31. PubMed ID: 10428930 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activities of telithromycin. Mikamo H; Yin XH; Ninomiya M; Tamaya T Chemotherapy; 2003 May; 49(1-2):62-5. PubMed ID: 12714813 [TBL] [Abstract][Full Text] [Related]
6. Relative antibacterial efficacy of clindamycin and metronidazole against Bacteroides fragilis in vitro and in experimentally infected mice. Dijkmans BA; Vaishnav J; Mattie H Chemotherapy; 1985; 31(4):297-303. PubMed ID: 4028873 [TBL] [Abstract][Full Text] [Related]
7. Synergism between penicillin, clindamycin, or metronidazole and gentamicin against species of the Bacteroides melaninogenicus and Bacteroides fragilis groups. Brook I; Coolbaugh JC; Walker RI; Weiss E Antimicrob Agents Chemother; 1984 Jan; 25(1):71-7. PubMed ID: 6142680 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess. Fu KP; Lasinski ER; Zoganas HC; Kimble EF; Konopka EA J Antimicrob Chemother; 1984 Dec; 14(6):633-40. PubMed ID: 6520063 [TBL] [Abstract][Full Text] [Related]
9. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis. Brook I Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944 [TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice. Brook I J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161 [TBL] [Abstract][Full Text] [Related]
11. Use of cephalosporins for prophylaxis and therapy of polymicrobial infection in mice. Brook I Antimicrob Agents Chemother; 1993 Jul; 37(7):1531-5. PubMed ID: 8363386 [TBL] [Abstract][Full Text] [Related]
12. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis. Bartlett JG; Dezfulian M; Joiner K Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635 [TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria. Wexler HM; Molitoris E; Molitoris D; Finegold SM J Antimicrob Chemother; 2001 Apr; 47(4):467-9. PubMed ID: 11266423 [TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant strains of the Bacteroides fragilis group. Aldridge KE; Stratton CW J Antimicrob Chemother; 1991 Nov; 28(5):701-5. PubMed ID: 1778873 [TBL] [Abstract][Full Text] [Related]
16. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752 [TBL] [Abstract][Full Text] [Related]
17. First report of metronidazole resistant, nimD-positive, Bacteroides stercoris isolated from an abdominal abscess in a 70-year-old woman. Otte E; Nielsen HL; Hasman H; Fuglsang-Damgaard D Anaerobe; 2017 Feb; 43():91-93. PubMed ID: 28011371 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron. Ibrahim KH; Gunderson BW; Hermsen ED; Hovde LB; Rotschafer JC Antimicrob Agents Chemother; 2004 Nov; 48(11):4195-9. PubMed ID: 15504841 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of telithromycin (HMR 3647) and seven other antimicrobial agents against anaerobic bacteria. Ackermann G; Schaumann R; Pless B; Claros MC; Rodloff AC J Antimicrob Chemother; 2000 Jul; 46(1):115-9. PubMed ID: 10882699 [TBL] [Abstract][Full Text] [Related]
20. Antibiotic penetration of experimental intra-abdominal abscesses. Galandiuk S; Lamos J; Montgomery W; Young S; Polk HC Am Surg; 1995 Jun; 61(6):521-5. PubMed ID: 7762902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]